Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zainab M. Al Shareef has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Decoding Chemobrain: Insights from Multi-omics Approaches

    by Munazza Ahmed, Ruba A. Zenati, Shab M. Alkhoujah, Ahmad Y. Abuhelwa, Shereen M. Aleidi, Mohammad A. Y. Alqudah, Waseem El-Huneidi, Eman Abu-Gharbieh, Zainab M. AlShareef, Karem H. Alzoubi, et al.

    Chemotherapy-induced cognitive impairment, widely known as chemobrain, has emerged as a pressing concern as cancer incidence and treatment success continue to rise worldwide. Patients frequently report persistent deficits in memory, attention, affective regulation, and executive function, which significantly diminish quality of life. While early explanations emphasized psychological causes, evidence now supports a biological basis involving oxidative stress, neuroinflammation, synaptic alterations, and blood-brain barrier disruption. Yet, the precise molecular mechanisms remain incompletely understood, in part due to methodological limitations of conventional neuroscience approaches. Recent advances in multi-omics technologies have opened new avenues to dissect the complexity of chemobrain at genomic, transcriptomic, proteomic, metabolomic, and lipidomic levels. Studies employing both untargeted discovery workflows and targeted validation strategies have revealed convergent disruptions in mitochondrial function, neurotransmitter pathways, and inflammatory signaling, despite differences across chemotherapeutic agents. Integrative analyses further highlight how these molecular perturbations align with behavioural deficits observed in preclinical and clinical settings. This review synthesizes current multi-omics evidence, emphasizing not only the shared downstream neurotoxic pathways across diverse chemotherapies but also the variability introduced by experimental design, tissue selection, and validation practices. Importantly, multi-omics profiling underscores the need for combination neuroprotective strategies, as chemotherapy-induced cognitive impairment arises from intertwined molecular insults rather than a single pathway. By consolidating mechanistic insights from multi-omics, this review aims to inform biomarker discovery, therapeutic innovation, and ultimately the development of precision strategies to mitigate the burden of chemobrain in cancer survivors.

  • Open Access

    Microbial dysbiosis and inferred functional profiling reveals the potential role of Methylobacterium in prostate cancer

    by Zainab M. Al Shareef, Rula M. Al-Shahrabi, Fatemeh Saheb Sharif-Askari, Burcu Yener, Poorna M. Bhamidimarri, Amal Bouzid, Iman M. Mamdouh Talaat, Riyad Bendardaf, Rifat A. Hamoudi, Sambhaji Mote, et al.

    Background and objective: Prostate cancer (PCa) is a leading malignancy in men, with a multifactorial aetiology involving genetic, hormonal, and microbial factors. Although emerging evidence implicates tumour-associated microbial communities in cancer biology, microbial signatures in PCa, particularly in Arab populations, remain underexplored. This study aimed to characterize the prostate tissue microbiota in an Arab cohort and explore associations with clinical features. Methods: In this retrospective study, 40 formalin-fixed paraffin-embedded (FFPE) prostate tissue samples (23 PCa and 17 benign prostatic hyperplasia [BPH]) were analysed using 16S rRNA gene sequencing. Microbial diversity, taxonomic composition, and predicted functional potential inferred from 16S data were assessed using DADA2 (v1.30.0), phyllode (v1.46.0), and PICRUSt2 (v2.5.2), with taxonomic classification based on the SILVA database (release 138). Beta diversity differences were tested using PERMANOVA (999 permutations), and differential abundance analyses were corrected using false discovery rate (FDR). Key findings and limitations: PCa tissues demonstrated higher alpha diversity than BPH samples, with greater heterogeneity in beta diversity. Among the identified genera, Methylobacterium was enriched in PCa samples and remained directionally consistent after multivariable adjustment. Exploratory analyses suggested higher abundance in advanced and deceased cases; however, survival findings were limited by sample size. Functional inference indicated enrichment of predicted pathways for carbohydrate and nitrogen metabolism. Conclusions: This exploratory study identified Methylobacterium as a candidate microbial signature associated with PCa in an Arab cohort. Given the modest sample size and the inferential nature of functional predictions, these findings require validation in larger prospective studies using direct metagenomic and metabolomic approaches.

  • Open Access

    Comprehensive BRCA1/2 mutation landscape in prostate cancer in the UAE and Arab population

    by Zainab M. Al Shareef, Rula M. Al-Shahrabi, Poorna Manasa Bhamidimarri, Burcu Yener, Amal Bouzid, Alaa Mohamed Hamad, Shirin Murad, Ahmed Elbarkouky, Fatemeh Saheb Sharif-Askari, Riyad Bendardaf, et al.

    Background: Prostate cancer (PCa) is the most common malignancy among men in the United Arab Emirates (UAE) and is often diagnosed at advanced stages with aggressive features. Germline mutations in DNA-repair genes, especially BRCA1 and BRCA2 , increase PCa risk, with BRCA2 conferring up to 8.6-fold and BRCA1 a 3.7-fold risk. The objective is to determine the prevalence, zygosity, and clinical significance of BRCA1/2 mutations in high-grade PCa among UAE and Arab patients and describe their potential role in disease aggressiveness. Methods: A retrospective analysis was performed on 40 archived formalin-fixed, paraffin-embedded prostate tissues (2011–2022), comprising 23 PCa and 17 benign prostatic hyperplasia (BPH). Targeted exon sequencing was performed. Variants were classified using ACMG/AMP criteria using ClinVar and Varchat. Associations between mutation patterns, zygosity, and tumor grade were evaluated. Results: BRCA1 mutations occurred in 47.5% of cases, all in exon 10, with 62.5% homozygosity; most frequent were c.794G>A and c.721G>A. BRCA2 mutations occurred in 55% of cases, mainly exon 11, with 68% homozygosity; c.5917A>C and c.5908T>A were most common. Homozygous mutations enriched in high-grade PCa (Grade Groups 3–5) suggested biallelic inactivation and homologous recombination repair deficiency. Several novel variants clustered in DNA repair domains, including BRCA1 coiled-coil and BRCA2 RAD51-binding. Conclusion: Our findings reveal a high prevalence of homozygous BRCA1/2 mutations, with the majority had aggressive disease phenotypes. Therefore, support the potential utility of PARP inhibitors as molecularly targeted therapeutic alternatives to conventional chemotherapy in mutation-positive patients. Furthermore, the identification of novel population-specific variants underscores the urgent need for ethnicity-informed genetic screening protocols, facilitating earlier detection of hereditary risk and enabling informed treatment stratification in United Arab Emirates and Arab men with PCa.

  • Artificial Intelligence and Multiomics Beyond PSA Screening in African and Middle Eastern Prostate Cancer Patients

    by Rula Al-Shahrabi, Omer S. Alkhnbashi, Rauda S. B. Almarri, Sarfraz Ahmad, Nelson C. Soares, Zainab Al Shareef

    Prostate cancer (PCa) remains a major global health burden, with incidence rising as populations age. The molecular, histological, and patient-specific heterogeneity of PCa underscores the urgent need for advanced strategies to improve detection and risk stratification. This review highlights how multiomics integration, including transcriptomics, DNA methylation, proteomics, and metabolomics, combined with artificial intelligence (AI), can validate biological mechanisms across molecular layers, thereby enhancing diagnostic reliability and biological relevance. While prostate-specific antigen (PSA) testing has significantly shaped PCa epidemiology, its limited specificity and sensitivity have led to widespread overdiagnosis and overtreatment, particularly of indolent tumors. These limitations are especially pronounced in underrepresented populations, notably men of African descent and those in the Middle East and North Africa (MENA) region, where PSA-based screening demonstrates reduced effectiveness. Despite advances in biomarker discovery, current datasets lack sufficient ethnic and regional diversity, raising concerns about the clinical validity and equity of AI-driven models. We argue that equitable precision oncology requires not only technological innovation but also the development of inclusive, demographically representative datasets. This review offers a forward-looking perspective on advancing PCa screening and stratification beyond PSA, with a particular emphasis on addressing the unmet clinical needs of African and Middle Eastern patients.


  • Incidence and risk factors of prostate cancer among the Northern and Eastern parts of the United Arab Emirates population

    by Zainab Al Shareef, Rula Al‐Shahrabi, Fatemeh Saheb Sharif‐Askari, Amna AlDhmanie, Younis Alshamsi, Abdulqadir Al Zarooni, Rabah Al Mahmoud, Sameh S. M. Soliman, Rabih Halwani, Riyad Bendardaf

    Background: Prostate cancer (PCa) is a prevalent disease worldwide. However, the incidence and patient‐specific risk factors of PCa in the Middle East, specifically in the United Arab Emirates, have not been previously reported.Methods: We conducted a retrospective cohort study on 2377 men diagnosed with either benign prostatic hyperplasia (BPH) or PCa in the Northern and Eastern regions of the United Arab Emirates, excluding the Western part, which includes Abu Dhabi. The study spanned from January 2012 and December 2021. To calculate the PCa incidence rate, we utilized the world age‐standardized incidence rates (W‐ASIR) categorized by age groups. Patient‐specific risk factors of PCa were identified through a multivariate logistic regression analysis of clinical data.Results: A total of 247 cases of PCa and 2130 cases of BPH were included in the study. In our cohort, the W‐ASIR for PCa was 21.3 per 100,000 men. The incidence of PCa showed an increasing trend with age, with the highest incidence observed among men aged 70 years and older. Accordingly, multivariate analysis revealed that age over 70 was associated with an increased risk of PCa (OR: 2.546, 95% confidence interval [CI]: 1.892−3.425, p < 0.01). On the other hand, preexisting conditions such as hypertension and diabetes mellitus were found to lower the risk of PCa (OR: 0.222, 95% CI: 0.163−0.302, p < 0.001) and (OR: 0.364, 95% CI: 0.205−0.648, p < 0.001), respectively. Additionally, metformin intake was associated with a reduced risk of PCa (OR: 0.385, 95% CI: 0.190−0.782, p = 0.008); while insulin usage increased the risk of PCa (OR: 2.586, 95% CI: 1.539−4.344, p < 0.001). Anti‐BPH medications such as phosphodiesterase inhibitors (OR: 0.223, 95% CI: 0.069−0.723, p = 0.012) or 5‐α reductase (OR: 0.206, 95% CI: 0.110−0.389, p < 0.000), were found to lower the risk of PCa.Conclusion: The findings underscore the high incidence of PCa in the United Arab Emirates, with age being a significant factor. Furthermore, the study highlights the influence of certain comorbidities and medications on the risk of developing PCa within the United Arab Emirates population.


  • Open Access

    Risks of prostate cancer and mortality in the city of Sharjah, United Arab Emirates

    by Zainab Al Shareef, Rula Al-Shahrabi, Fatemeh Saheb Sharif-Askari, Younis Alshamsi, Abdulqadir Al Zarooni, Noura AlKhayyal, Sameh S. M. Soliman, Riyad Bendardaf, Rabih Halwani

    Background: Prostatic hyperplasia (BPH) and prostate cancer (PCa) are common age-related diseases in men. According to World Health Organization (WHO), PCa is the second most common cancer among Emirati men. This study aimed to identify the risk factors associated with PCa and mortality in a cohort diagnosed with PCa between 2012 and 2021 in Sharjah, United Arab Emirates (UAE).Methods: The data collected in this retrospective case-control study included patient demographics and comorbidities, as well as PCa markers such as prostate-specific antigen (PSA), prostate volume, prostate-specific antigen density (PSAD), and Gleason scores. Risk factors for PCa were assessed using multivariate logistic regression analysis, and factors associated with all-cause mortality in PCa patients were evaluated using Cox-proportional hazard analysis.Results: Of the 192 cases analyzed in this study, 88 were diagnosed with PCa and 104 were diagnosed with BPH. Regarding risk factors for PCa, a higher risk of PCa was associated with age 65 or older (OR=2.76, 95% confidence interval (CI): 1.04-7.30; P=0.038) and serum PSAD greater than 0.1 ng/mL2 (OR=3.48, 95% CI:1.66-7.32; P=0.001), whereas being of UAE nationals (OR=0.40, 95% CI:0.18-0.88; P=0.029) were associated with lower risk of PCa, after adjusting for patient demographics and comorbidities. Moreover, regarding cancer markers, higher serum PSA level (P=0.003) and smaller prostate volume (P=0.028) were associated with a higher risk of PCa, after adjusting with patients’ age and BMI. Additionally, a high-grade Gleason score was associated with an increased risk of all-cause mortality after adjusting for patient’s age and BMI (hazard ratio, aHR= 2.3, 95% CI:1.3-4.1; P= 0.016).Conclusion: This study found that age 65 or older and serum PSAD greater than 0.1 ng/mL2 are risk factors for PCa, while UAE nationality is associated with a lower risk. PSAD may be a better screening marker for PCa compared to traditional markers such as PSA and prostate volume.


  • Open Access

    Nanocarrier Drug Conjugates Exhibit Potent Anti-Naegleria fowleri and Anti-Balamuthia mandrillaris Properties

    by Ruqaiyyah Siddiqui, Anania Boghossian, Muhammad Kawish, Tooba Jabri, Muhammad Raza Shah, Tengku Shahrul Anuar, Zainab Al-Shareef, Naveed Ahmed Khan

    Given the opportunity and access, pathogenic protists (Balamuthia mandrillaris and Naegleria fowleri) can produce fatal infections involving the central nervous system. In the absence of effective treatments, there is a need to either develop new antimicrobials or enhance the efficacy of existing compounds. Nanocarriers as drug delivery systems are gaining increasing attention in the treatment of parasitic infections. In this study, novel nanocarriers conjugated with amphotericin B and curcumin were evaluated for anti-amoebic efficacy against B. mandrillaris and N. fowleri. The results showed that nanocarrier conjugated amphotericin B exhibited enhanced cidal properties against both amoebae tested compared with the drug alone. Similarly, nanocarrier conjugated curcumin exhibited up to 75% cidal effects versus approx. 50% cidal effects for curcumin alone. Cytopathogenicity assays revealed that the pre-treatment of both parasites with nanoformulated-drugs reduced parasite-mediated host cellular death compared with the drugs alone. Importantly, the cytotoxic effects of amphotericin B on human cells alone were reduced when conjugated with nanocarriers. These are promising findings and further suggest the need to explore nanocarriers as a means to deliver medicine against parasitic infections.


  • Open Access

    Dickkopf-3: An Update on a Potential Regulator of the Tumor Microenvironment

    by Zainab Al Shareef, Mai Nidal Asad Ershaid, Rula Mudhafar, Sameh S. M. Soliman, Robert M. Kypta

    Dickkopf-3 (Dkk-3) is a member of the Dickkopf family protein of secreted Wingless-related integration site (Wnt) antagonists that appears to modulate regulators of the host microenvironment. In contrast to the clear anti-tumorigenic effects of Dkk-3-based gene therapies, the role of endogenous Dkk-3 in cancer is context-dependent, with elevated expression associated with tumor promotion and suppression in different settings. The receptors and effectors that mediate the diverse effects of Dkk-3 have not been characterized in detail, contributing to an ongoing mystery of its mechanism of action. This review compares the various functions of Dkk-3 in the tumor microenvironment, where Dkk-3 has been found to be expressed by subpopulations of fibroblasts, endothelial, and immune cells, in addition to epithelial cells. We also discuss how the activation or inhibition of Dkk-3, depending on tumor type and context, might be used to treat different types of cancers.


  • Optimum inhibition of MCF-7 breast cancer cells by efficient targeting of the macropinocytosis using optimized paclitaxel-loaded nanoparticles

    by Razan B. Al-Humaidi, Bahgat Fayed, Sarra B. Shakartalla, Jayalakshmi Jagal, Manju N. Jayakumar, Zainab M. Al Shareef, Suleiman I. Sharif, Ayman Noreddin, Mohammad H. Semreen, Hany A. Omar, et al.